Our results demonstrated that compared to the control CD133+CD44+ CCSCs, colon cancer cells from PRDX2 knockdown CD133+CD44+ CCSCs exhibited reduced tumor incidence, tumor size and tumor growth in vivo (Figure 3), suggesting that PRDX2 knockdown significantly suppresses the tumorigenic capacity of CD133+CD44+ CCSCs in vivo. This evidence concerns the gene CD44 and neoplasm.